GlassScriptPhysician profile
Murat Polar
NPI 1558437426
$7,973.27
in general payments reported to CMS, 2019-2025
24 companies · $3,367 in 2025
The $3,367 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16.98 · 2020: $178 · 2021: $95.09 · 2022: $231 · 2023: $1,092 · 2024: $2,993 · 2025: $3,367.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,400 · Education: $52.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,399.95 |
| Education | $52.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,366.56 | 2022-2025 | Caplyta |
| Abbvie INC. | $1,202.17 | 2022-2025 | |
| Vanda Pharmaceuticals INC. | $1,124.51 | 2020-2025 | Fanapt, Hetlioz |
| Axsome Therapeutics, INC. | $876.03 | 2023-2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $848.96 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Gilead Sciences, INC. | $805.09 | 2023-2025 | Epclusa |
| Braeburn INC. | $558.58 | 2023-2025 | Brixadi |
| Indivior INC. | $320.75 | 2020-2025 | Sublocade |
| Orexo US, INC. | $199.61 | 2023-2025 | Zubsolv |
| Tris Pharma INC | $168.49 | 2024-2025 | Dyanavel Xr |
| Mdd US Operations, LLC | $111.64 | 2020 | |
| Corium, LLC | $100.78 | 2024-2025 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $48.00 | 2025 | Trintellix |
| Almatica Pharma LLC | $44.55 | 2024-2025 | Loreev Xr |
| Collegium Pharmaceutical, INC. | $32.21 | 2022-2025 | Jornay Pm |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $27.81 | 2023 | Ingrezza |
| Vertex Pharmaceuticals Incorporated | $21.09 | 2025 | |
| Mylan Specialty L.P. | $21.05 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $17.58 | 2022 | |
| Kaleo, INC. | $16.98 | 2019 | |
| Avanir Pharmaceuticals, INC. | $16.94 | 2021 | |
| Lilly USA, LLC | $15.65 | 2020 | |
| Alkermes, INC. | $14.34 | 2025 | Aristada, Lybalvi |
| Idorsia Pharmaceuticals US INC | $13.90 | 2024 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Murat Polar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.